A Phase 3 interventional study of oral beclomethasone 17,21-dipropionate and Placebo in Acute Gastrointestinal Graft vs Host Disease, sponsored by Soligenix. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.
Sponsored by Soligenix · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.
Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 32nd largest by enrollment of the 389 interventional ones that give a count, is one of 14 that started in 2009, is one of 40 in phase 3, and was the 191st registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 7+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regenerative Ocular Immunobiologics LLC · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Sawa Ito, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 145 · Phase 2 227 · Phase 3 48 · Phase 4 5
First in 1986; this study’s year is marked. 14 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 30 across the 389 interventional studies, 81 across the 43 observational. Of the 347 that completed or were terminated, 166 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 454 have an industry lead sponsor. The 10 most frequent:
Soligenix is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Soligenix has 2 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Graft vs Host Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776210Phase 3Regenerative Ocular Immunobiologics LLCStudy of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) | 2027-03-31 |
| NCT06649201Case Comprehensive Cancer CenterVulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | 2026-11 |
| NCT05675930Memorial Sloan Kettering Cancer CenterA Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | 2026-12-22 |
| NCT04044365National Cancer Institute (NCI)Pediatric cGVHD Symptom Scale | 2026-12-31 |
| NCT03533816University of Kansas Medical CenterExpanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | 2027-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 454 studies in Graft vs Host Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug
Drug: oral beclomethasone 17,21-dipropionate
Control
Drug: Placebo
Two tablets QID for 50 days
Also known as: orBec, BDP
Two tablets QID for 50 days
The Proportion of Subjects With GVHD Treatment Failure
The primary endpoint is the occurrence (yes, no) during the 80-day study period of GVHD treatment failure defined as use of prednisone or equivalent IV corticosteroids at doses higher than stated in the protocol, or use of any additional other glucocorticoid (including unblinded BDP) or addition of other immunosuppressant medications, in response to uncontrolled signs or symptoms of GVHD
Time frame: Day 80
Cumulative Exposure to Prednisone
Time frame: Day 80
Survival Status
Time frame: Day 200
| Milestone | Active | Placebo |
|---|---|---|
| Started | 70 | 70 |
| Completed | 54 | 53 |
| Not completed | 16 | 17 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 8 | 9 |
The primary endpoint is the occurrence (yes, no) during the 80-day study period of GVHD treatment failure defined as use of prednisone or equivalent IV corticosteroids at doses higher than stated in the protocol, or use of any additional other glucocorticoid (including unblinded BDP) or addition of other immunosuppressant medications, in response to uncontrolled signs or symptoms of GVHD
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Day 1 to Day 80. Non-serious events are listed at a 1.43% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | — | 32/70 (45.7%) | 70/70 (100%) |
| Placebo | — | 28/70 (40%) | 70/70 (100%) |
| Event | Active | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 4/70 | 2/70 |
| FeverGeneral disorders | 2/70 | 1/70 |
| NauseaGastrointestinal disorders | 2/70 | 1/70 |
| VomitingGastrointestinal disorders | 2/70 | 1/70 |
| CMV infectionInfections and infestations | 2/70 | 0/70 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/70 | 0/70 |
| Renal failureRenal and urinary disorders | 2/70 | 1/70 |
| Acute myeloid leukemia progressionBlood and lymphatic system disorders | 0/70 | 1/70 |
| Angiopathic AnemiaBlood and lymphatic system disorders | 0/70 | 1/70 |
| Leukemic RelapseBlood and lymphatic system disorders | 0/70 | 1/70 |
| Event | Active | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 33/70 | 17/70 |
| NauseaGastrointestinal disorders | 22/70 | 21/70 |
| FatigueGeneral disorders | 17/70 | 22/70 |
| Abdominal painGastrointestinal disorders | 20/70 | 14/70 |
| HypertensionVascular disorders | 19/70 | 7/70 |
| VomitingGastrointestinal disorders | 12/70 | 17/70 |
| Decreased appetiteMetabolism and nutrition disorders | 16/70 | 13/70 |
| Cytomegalovirus infectionInfections and infestations | 15/70 | 11/70 |
| PyrexiaGastrointestinal disorders | 12/70 | 9/70 |
| HyperglycaemiaMetabolism and nutrition disorders | 11/70 | 12/70 |
DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.
| Age, Categorical(Participants) | Active | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 62 | 66 | 128 |
| >=65 years | 8 | 4 | 12 |
| Sex: Female, Male(Participants) | Active | Placebo | Total |
|---|---|---|---|
| Female | 34 | 36 | 70 |
| Male | 36 | 34 | 70 |
The record gives a start of Oct 2009, a primary completion of Dec 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Soligenix